CTLA4 and acute kidney injury: Our study reveals that the incidence of AKI has kept growing in recent years (anti-PD-1 ~5%, anti-PD-L1 ~5%, anti-CTLA-4 ~8%, anti-PD-1 + anti-CTLA-4 ~6%), leaving outdated the previous incidence values of 2–3% for monotherapies and 5% for combined therapies [70].